

GE Healthcare

Strong bones.
It's vital.

Achilles Bone Ultrasonometers




You.

Where vitality begins.

As a health professional, you help your patients seek and achieve lasting quality of life. It is you who opens the door to bone health assessment, diagnosis, and treatment or prevention. Achilles* is here to help. It makes proven fracture risk assessment widely accessible. And that's vital for you and your patients.

Achilles offers accurate fracture risk assessment that is comfortable for patients and convenient for operators. All to help you provide better care to more patients.





Fracture risk assessment proven in 11 prospective clinical studies.

The accuracy of the Achilles family of bone ultrasonometers has been proven in more clinical studies than any other quantitative ultrasound (QUS) device.¹ Results with Achilles closely match the efficiency of DXA, the industry's gold standard, in assessing fracture risk of the hip and spine.^{1,2,3}

Osteoporotic fracture risk assessment as discriminating as DXA at the hip and spine.

The osteoporotic fracture risk assessment provided by Achilles closely matches prevalence as defined by central DXA (see chart below).¹ Yet it's fast and affordable.

Its high negative predictive value — 97 percent for 50- to 59-year-old Caucasian women — makes Achilles especially useful for discriminating between those not at risk for fracture and those in need of further evaluation by central DXA.⁴


Additionally, Achilles has proven long-term precision, making it useful for monitoring bone changes.^{5,6,7} It's the only QUS device cleared for monitoring by the Food and Drug Administration.

Clinical confidence is based on many features:

- ▶ Dynamic signal strength compensation allows measurement over a wide range of bone density
- ▶ Bi-directional measurement ensures a consistent reading
- ▶ Measurement site temperature is controlled for more accuracy
- ▶ Results expressed as Stiffness Index — a composite of Speed of Sound (SOS) and Broadband Ultrasound Attenuation (BUA) — compensate for the effect of heel width and temperature
- ▶ Real-time image provides visual confirmation of proper heel placement (Achilles Insight only)

Comparison of Achilles and competitive ultrasonometers to DXA for osteoporosis testing¹

Percentage of 60-year-old women that tested positive for osteoporosis



Better care can be anywhere with Achilles

Achilles provides fast, affordable, easily portable care, helping you reach more patients with the accurate assessment and follow-up care they need.

Certainty.



Awareness
and education
can lead to
strength and
vitality.


Protect their vitality.

Comfort.


A quick and comfortable exam is the first step toward vitality.

With Achilles, the patient experience is pleasant. The exam is quick: just a few minutes from shoes off to shoes on. The patient is seated. No messy gels are needed. Its ultrasound technology emits no ionizing radiation.

Warm, water-filled membranes hug the heel.



A large, easy-to-read color display tilts back and forth.



Convenience.

Efficient, customizable workflow.

Your staff will appreciate the simplicity of Achilles. It's easy for technicians to learn and to use, and it requires no special rooms, no formal training, and no licensing. Results are concise and easy to interpret.

Along with rugged durability, Achilles boasts plenty of technical features. A large, easy-to-read color display tilts back and forth. Reports print out in full color and full size. The on-board memory stores up to 2,000 patient records. And customizable measurement workflows allow you to select which data to collect and report:

- ▶ Prevalence data
- ▶ Clinical risk factors
- ▶ Patient identification data



Facility Name
Street Address
City, State, Zip
Phone Number

Name: _____ Patient ID: _____
Age / Date of Birth: 50 yrs. Physician: _____
Sex: Male Test Date: _____
Heel: Left

STIFFNESS **T SCORE**

AGE (Years)

Stiffness Index: 72 T-Score: -1.8 BUA: 54.4
% Young Adult: 72 Z-Score: _____ SOS: 1500.0
% Age Matched: _____

Clinical Risk Factors:
Previous fracture, Smokes, Drinks

Comments: Medium risk of osteoporotic fracture.

Follow Up: None 6 Months 12 Months 18 Months 24 Months

GE Healthcare Lunar Achilles EXPII SN: 99999 Software Version 1.0

imagination at work

Vitality for your patients means vitality for your business

When more patients know their risk of fracture, there are benefits for you and your business, too. The ongoing monitoring capabilities of Achilles, as well as the fast, comfortable exam, all can contribute to increased patient loyalty.

Do you want to raise awareness of osteoporosis among the general public? Assess risk to make the most efficient use of your central DXA system? Or provide direct osteoporosis management? Whatever your goal, Achilles can help.

► Contact your GE Healthcare representative for more information on Achilles

Leading hospitals, clinics, and physicians trust Achilles to help provide better care for their patients.

1. Krieg M-A, Barkmann R, Gonnelli S, et al. Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions. *J Clin Densitom: Assessment of Skeletal Health*. 2008;11(1):163-187.
2. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. *Lancet*. 1996;348(9026):511-514.
3. Glüer Claus C, Eastell R, Reid DM, et al. Association of Five Quantitative Ultrasound Devices and Bone Densitometry With Osteoporotic Vertebral Fractures in a Population-Based Sample: The OPUS Study. *J Bone Miner Res*. 2004;19(5):782-793.
4. Simon D, Boring III JR. Chap. 6: Sensitivity, Specificity, and Predictive Value. In: HK Walker, WD Hall, JW Hurst, ed. *Clinical Methods: The History, Physical, and Laboratory Examinations*, 3rd edition. Boston: Butterworths; 1990.
5. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Rossi S, Gennari C. Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: A longitudinal study. *Osteoporos Int*. 1996;6(4):303-307.
6. Giorgino R, Paparella AP, Lorusso D, Mancuso S. Effects of oral alendronate treatment and discontinuance on ultrasound measurements of the heel in postmenopausal osteoporosis. *North American Menopausal Society*, September 1996.
7. Gonnelli S, Cepollaro C, Montagnani A, et al. Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. *Osteoporos Int*. 2002;13(5):415-421.

©2011 General Electric Company – All rights reserved.

GE and GE Monogram are trademarks of General Electric Company. *Achilles is a trademark of General Electric Company. **All third-party trademarks are the property of their respective owner.

General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your GE representative for the most current information.

GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC, a General Electric company, doing business as GE Healthcare

**Lunar Product Division:
Americas**

GE Healthcare Lunar
Global Headquarters
PO Box 7550
Madison, WI 53707-7550
T: +1-800-535-7339
F: +1-608-223-2482

Europe, Middle-East & Africa

GE Healthcare Lunar
Kouterveldstraat 20
B-1831 Diegem, Belgium
T: +32-2-7197217
F: +32-2-7197359
info.lunar@ge.com

Asia & Pacific

GE Healthcare Lunar
3/F GE China Technology Park
No. 1 Hua Tuo Road
Shanghai 201203, China
T: +86-21-38777888 (Ext. 60128 or 60480)
F: +86-21-38777451

About GE Healthcare:

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "**healthmagination**" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

To receive Lunar News online, please register for **SmartMail**.
Go to www.gehealthcare.com/company/smartmail.html
and register to automatically receive the newsletter.



imagination at work